Jasper Therapeutics (JSPR) Cash from Investing Activities (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Cash from Investing Activities of $1000.0 for Q2 2025, up 100.64% year-over-year from $498.41 in Q2 2024, and down 75.0% quarter-over-quarter from $4000.0 in Q1 2025.
Jasper Therapeutics (JSPR) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $1000.0 for Q2 2025.
- In Q2 2025, Cash from Investing Activities rose 100.64% year-over-year to $1000.0; the TTM figure through Dec 2025 stood at $5000.0 (up 100.94% YoY), while the FY2025 annual figure was $5000.0, up 100.94% from the prior year.
- Cash from Investing Activities for Q2 2025 stood at $1000.0, down from $4000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $4000.0 in Q1 2025, with the low at -$960000.0 in Q1 2021.
- The 5-year median for Cash from Investing Activities is -$157000.0 (2024), against an average of -$223411.8.
- The sharpest annual moves came in 2021 and 2025: Cash from Investing Activities slumped 4060.56% in 2021, then surged 116.0% in 2025.
- Jasper Therapeutics' Cash from Investing Activities stood at -$711000.0 in 2021, then surged by 88.47% to -$82000.0 in 2022, then plunged by 180.49% to -$230000.0 in 2023, then soared by 66.96% to -$76000.0 in 2024, then soared by 101.32% to $1000.0 in 2025.
- Business Quant data shows JSPR's Cash from Investing Activities at $1000.0 in Q2 2025, $4000.0 in Q1 2025, and -$76000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -76,000.00 |
| Dec 31, 2024 | -76,000.00 |
| Sep 30, 2024 | -274,000.00 |
| Sep 30, 2024 | -274,000.00 |
| Jun 30, 2024 | -157,000.00 |
| Jun 30, 2024 | -157,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Dec 31, 2023 | -230,000.00 |
| Dec 31, 2023 | -230,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -82,000.00 |
| Dec 31, 2022 | -82,000.00 |